Pfizer (NYSE:PFE) Shares Up 1.1% – Still a Buy?

Pfizer Inc. (NYSE:PFE) shares rose 1.1% during mid-day trading on Thursday . The company traded as high as $25.89 and last traded at $25.86. Approximately 54,988,627 shares changed hands during trading, an increase of 16% from the average daily volume of 47,469,805 shares. The stock had previously closed at $25.58.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive pivotal-trial news: Pfizer reported positive results from Cohort 3 of the BREAKWATER trial for BRAFTOVI + cetuximab + FOLFIRI in BRAF V600E metastatic colorectal cancer — a meaningful oncology readthrough for future sales and label expansion. Why Pfizer Inc. (PFE) is One of the Best Affordable Stocks Under $30
• Positive Sentiment: Regulatory push: CEO said Pfizer is pursuing an FDA priority review voucher — could accelerate approvals and shorten time-to-revenue for qualifying assets. Pfizer CEO Says Company Is Pushing for FDA Priority Review Voucher
• Positive Sentiment: Migraine program progress: Pfizer completed a key China Phase 3 trial for rimegepant and is advancing a CGRP migraine asset with a new bioequivalence study — may support label expansion and China commercial potential. Pfizer Completes Key China Phase 3 Trial for Migraine Drug Rimegepant
• Positive Sentiment: Real-world evidence study: Pfizer updated the TOFAst observational study in ulcerative colitis — positive real-world data can support prescribing and payer decisions if results are favorable. Pfizer’s TOFAst Real-World Study in Ulcerative Colitis: What Investors Should Watch
• Positive Sentiment: Manufacturing and formulation work: Pfizer initiated bioequivalence studies for a prazosin manufacturing shift and for a CGRP migraine formulation — these moves reduce supply risk and can lower cost/expand access long-term. Pfizer Advances Prazosin Manufacturing Shift With New Bioequivalence Study
• Neutral Sentiment: Analyst/investor views: Commentary pieces (Seeking Alpha, TipRanks) pitch Pfizer as a value play given its dividend, pipeline and recent valuation — useful context for longer-term investors but not immediate catalysts. Pfizer: The Most Intriguing Value Play Of 2026
• Neutral Sentiment: Institutional ownership: Reports note ~66% institutional ownership — indicates large, stable holders but also potential for outsized moves if institutions rebalance. Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 66% of the company
• Negative Sentiment: Guidance and valuation pressure: Analysts flagged that Pfizer’s market cap fell over $7B in a month after weak 2026 guidance — this continues to weigh on sentiment and caps upside despite positive pipeline news. PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on PFE shares. Scotiabank began coverage on shares of Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective on the stock. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Cowen reiterated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Citigroup assumed coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price objective on the stock. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $27.88.

Pfizer Stock Up 1.1%

The firm’s fifty day moving average is $25.31 and its 200-day moving average is $24.98. The company has a market capitalization of $147.03 billion, a P/E ratio of 15.03 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date is Friday, January 23rd. Pfizer’s payout ratio is 100.00%.

Institutional Trading of Pfizer

Several institutional investors have recently modified their holdings of PFE. Horizon Financial Services LLC lifted its holdings in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares during the period. Curio Wealth LLC raised its position in shares of Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,098 shares during the last quarter. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer in the second quarter worth approximately $29,000. Grey Fox Wealth Advisors LLC bought a new stake in Pfizer in the third quarter valued at approximately $29,000. Finally, Howard Hughes Medical Institute acquired a new stake in Pfizer during the 2nd quarter valued at approximately $30,000. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.